Our Partnerships
Boston, MA, and Bethesda, MD
Window Therapeutics, Inc, announced a foundational partnership with the National Foundation for Cancer Research (NFCR) through its AIM-HI Accelerator Fund (AIM-HI) biotechnology innovation award program. As part of the collaboration, Window was awarded seed-funding to enable laboratory and operations start-up to advance the company’s lead cancer programs and novel Bottle-brush Analogue Macromolecule (BAM) platform technology. Window’s BAM platform modifies the therapeutic window of small molecule ,immune-based, and combination drug treatments to maximize efficacy specifically within disease sites.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the NCL to perform preclinical efficacy and toxicity testing of nanoparticles.